Testing Menu

Testing Services Offered

Drug Toxicology Testing

Presumptive Urine Drug Screening:

A presumptive drug screen is a qualitative diagnostic test that provides an initial assessment of the presence and approximate quantity of legal or illegal drugs in a person's system. This type of screening is commonly used to identify potential drug abuse, monitor substance abuse issues, or evaluate drug intoxication or overdose. Presumptive drug screening can be conducted rapidly, allowing for timely results.

Confirmatory Drug Testing:

Confirmatory drug testing, also referred to as definitive drug testing, is employed when there is a need to identify specific medications, illicit substances, and their metabolites with greater precision. Definitive urine drug testing (UDT) provides detailed reports on the absence or presence of drugs in concentrations measured in ng/ml (nanograms per milliliter). These tests, whether qualitative or quantitative, aim to identify the actual usage or non-usage of a particular drug. They can pinpoint the presence of specific drugs and their associated metabolites, providing a more comprehensive understanding of a person's drug profile.

COVID + Influenza A/B

Conducting a combined COVID and flu test offers several advantages and benefits that make it a valuable diagnostic tool. Here's a description of why testing for both COVID-19 and the flu simultaneously is advantageous:

Comprehensive Assessment: Testing for both COVID-19 and flu in a single test allows for a comprehensive assessment of respiratory illnesses. Since the symptoms of COVID-19 and the flu can overlap, a combined test provides a more accurate and efficient diagnosis by ruling out one or both conditions. This helps healthcare providers make informed decisions regarding patient care and appropriate treatment strategies.
Time and Resource Efficiency: Administering a single test for both COVID-19 and flu saves valuable time and resources compared to conducting separate tests for each condition. It streamlines the testing process, reduces the need for multiple sample collections, and minimizes the burden on patients and healthcare systems. This efficiency is especially crucial during flu season or in situations where COVID-19 and flu cases coexist.
Differentiating Viral Infections: By testing for both COVID-19 and flu simultaneously, healthcare professionals can distinguish between the two viral infections more accurately. This differentiation is important for epidemiological surveillance, tracking the prevalence of each virus, and implementing appropriate public health measures.
Preventing Transmission: Identifying individuals infected with both COVID-19 and flu helps in implementing timely isolation and quarantine measures. It aids in preventing the further spread of both viruses, protecting vulnerable populations, and reducing the strain on healthcare resources.
Enhanced Patient Management: Diagnosing both COVID-19 and flu concurrently allows for better patient management. It helps healthcare providers determine the most appropriate treatment options, initiate appropriate isolation measures, and provide targeted care to minimize the risk of complications and promote a speedy recovery.

In summary, conducting a combined COVID and flu test offers a more comprehensive assessment, improves efficiency, aids in differentiating viral infections, prevents transmission, and enhances patient management. By considering both infections simultaneously, healthcare providers can make well-informed decisions and deliver optimal care to their patients.

Onychomycosis Nail Fungus

Conventional laboratory diagnosis of onychomycosis has often relied on limited techniques, such as direct microscopic examination using potassium hydroxide (KOH) preparation. However, this approach has significant drawbacks as it fails to identify the specific genus, species, or pathogen responsible for the fungal infection. Additionally, it lacks the ability to differentiate between yeasts and molds. Consequently, false negative results are common, leading to inappropriate care or a lack of treatment, particularly in high-risk individuals, where a negative result does not rule out fungal infection.

The limitations of conventional diagnostic methods are evident in their lack of specificity, sensitivity, and time to diagnosis. Even when fungal cultures are attempted, failure to isolate the pathogen occurs in a substantial percentage of cases, and the process takes several weeks. Furthermore, histopathological testing, such as periodic acid-Schiff (PAS) staining, improves sensitivity by detecting the presence or absence of fungal elements but does not identify the specific organism.

Fortunately, the emergence of molecular technology, particularly the polymerase chain reaction (PCR) assay, has revolutionized the field of onychomycosis diagnosis. PCR testing, a highly sensitive and specific method, allows for the detection of various microorganisms, including fungal pathogens. In the case of onychomycosis, PCR testing amplifies specific DNA sequences of dermatophyte fungus, providing rapid and accurate identification.

The advantages of PCR testing over conventional methods are multifold. Firstly, PCR testing significantly improves sensitivity, enabling the detection of causative fungi in nail specimens from patients suspected of having onychomycosis. Secondly, PCR testing offers remarkable speed, delivering results within 24 hours, compared to the days or weeks required by traditional techniques. This expedited diagnosis facilitates prompt initiation of appropriate treatment, leading to improved patient outcomes.

The enhanced time efficiency of PCR testing not only allows for quicker diagnosis but also ensures that patients receive the right medication, at the right dose, sooner. By accurately identifying the fungal pathogen responsible for onychomycosis, clinicians can tailor treatment plans accordingly, maximizing therapeutic effectiveness.

In summary, the utilization of PCR testing for onychomycosis diagnosis represents a significant breakthrough in the field. Its ability to provide rapid, sensitive, and specific results surpasses the limitations of conventional methods. By expediting diagnosis and facilitating targeted treatment, PCR testing serves as a valuable and indispensable diagnostic tool in identifying fungal pathogens, enabling patients to receive appropriate care promptly.

Chronic Wound Care Testing

The healing trajectory of chronic wounds can be hindered by various host impairments, even when effectively controlled. It has become increasingly evident that bacterial bioburden, present in all chronic wounds, plays a significant role in healing failure. Until recently, the lack of adequate diagnostic tools to assess bioburden has posed a challenge. Standard microbiology cultures, while capable of identifying surface organisms, often failed to identify the organisms within the bioburden, accounting for over 80% of cases. To shed light on chronic wounds, extensive studies have been conducted, revealing two crucial points:

Chronic wounds harbor polymicrobial infections, comprising diverse microorganisms such as bacteria and yeast, functioning as a cooperative community.
This community frequently forms extensive biofilms, further complicating the wound healing process.

The advent of molecular diagnostics has transformed wound care, enabling personalized approaches and substantially enhancing healing success rates. One of the notable molecular techniques employed is Polymerase Chain Reaction (PCR), which targets and amplifies specific DNA sequences, allowing their detection. PCR relies on thermal cycling, involving repeated heating and cooling to facilitate DNA melting and enzymatic replication. By amplifying bacterial DNA, PCR can identify bacteria without the need for bacterial cultures to be grown in a microbiology laboratory. This technology exhibits exceptional sensitivity, specificity, and rapid turnaround time, with results obtainable within hours.

Since the implementation of PCR in evaluating chronic wound patients, intriguing discoveries have emerged. Traditional culture techniques often yielded results limited to bacteria such as Staphylococcus aureus. However, PCR analysis unveiled a broader range of bacteria, fungi (yeast), including anaerobes, and other challenging-to-culture organisms that colonize chronic wounds. Without PCR analysis, these anaerobic organisms, fungi, and other microorganisms would have remained undetected. Notably, when antibiotics targeting these previously unidentified microorganisms were employed, patients displayed positive responses to the therapy.

By harnessing the power of PCR technology, the care of chronic wound patients has been revolutionized. Accurate identification of diverse microbial communities within wounds allows for targeted treatment strategies, tailored to the specific pathogens present. This personalized approach not only improves therapeutic outcomes but also optimizes the use of antibiotics by addressing previously overlooked organisms. The sensitivity, specificity, and speed of PCR analysis have proven instrumental in transforming wound care, paving the way for more effective and successful healing interventions.

In summary, the utilization of molecular diagnostics, particularly PCR, has revolutionized chronic wound care. By uncovering the complex microbial communities residing within chronic wounds, personalized treatment plans can be devised, leading to improved healing outcomes. PCR's ability to rapidly detect a broad spectrum of microorganisms offers a valuable tool in identifying previously missed pathogens, enabling targeted antibiotic therapy and enhancing the overall success of wound management.

UTI Diagnostic Methods: Comparing UTI PCR and UTI Culture

UTI Molecular Diagnostic Screening: The introduction of UTI PCR (Polymerase Chain Reaction) testing has revolutionized the diagnosis of urinary tract infections (UTIs). This molecular diagnostic method offers numerous advantages over traditional UTI culture screening.

One significant benefit is the speed of UTI PCR testing. With accurate results available within hours, healthcare providers can promptly initiate appropriate treatment, leading to improved patient outcomes. In contrast, UTI culture screening typically requires 3-5 days to complete, potentially causing delays in diagnosis and treatment.

UTI PCR testing also excels in accuracy. By identifying the DNA of specific pathogens, UTI PCR provides precise detection of the exact pathogen causing the infection. In contrast, UTI culture screening relies on the growth of microbes in a culture medium, which poses inherent risks of missing certain pathogens and compromising specificity and sensitivity.

Another advantage of UTI PCR testing is its ability to detect low levels of microbial presence. Rather than relying on the volume of microbes in the sample, UTI PCR focuses on the presence of pathogen DNA. This high sensitivity enables the detection of co-infections with multiple pathogens, providing a comprehensive understanding of the UTI profile.

Furthermore, UTI PCR reports antibiotic resistance, enabling physicians to make accurate and efficient treatment decisions. This information helps guide the selection of appropriate antibiotics, reducing the risk of ineffective treatment and the development of antibiotic resistance.

UTI Culture Screening: While UTI culture screening has been the traditional method for diagnosing UTIs, it has several limitations compared to UTI PCR testing.

One major drawback of UTI culture screening is the extended time required for results. The 3-5 day turnaround time can lead to delays in initiating treatment, potentially allowing the infection to worsen and increasing the risk of complications. Moreover, the use of antibiotics prior to sample collection can impact culture results, leading to false-negative outcomes and hindering accurate diagnosis.

Specificity and sensitivity are also compromised in UTI culture screening. The reliance on microbial growth in a culture medium makes it challenging to detect all pathogens present in the sample. This limitation increases the risk of missing important pathogens and reduces the overall accuracy of the test.

Additionally, UTI culture screening has limited capabilities in detecting co-infections. The culture method typically focuses on identifying 1-2 microorganisms, potentially overlooking the presence of other pathogens that may contribute to the UTI.

In summary, UTI PCR testing offers significant advantages over UTI culture screening. Its rapid turnaround time, high specificity and sensitivity, ability to detect low microbial presence, and provision of antibiotic resistance information contribute to more accurate and efficient diagnosis and treatment of UTIs. By leveraging the benefits of UTI PCR, healthcare providers can enhance patient care and optimize treatment outcomes.

STD Testing

According to national guidelines, it is recommended to undergo annual screenings under the following circumstances:

Sexually active women under the age of 25.
Women over the age of 25 who are at risk of sexually transmitted infections (STIs), such as engaging in sexual activity with a new partner or multiple partners.
Men who have sex with men.
Individuals with HIV.
Individuals who have been victims of sexual assault or forced sexual activity.

Healthcare providers typically screen for chlamydia and gonorrhea by conducting a urine test or swabbing the penis in men or the cervix in women. The collected sample is then analyzed in a laboratory. Regular screening is crucial because these infections can be asymptomatic, meaning individuals may be unaware of their infection status.

In addition to chlamydia and gonorrhea, there are other infections that require screening:

HIV, Syphilis, and Hepatitis: The Centers for Disease Control and Prevention (CDC) recommends routine HIV testing for adolescents and adults between the ages of 13 and 64. Younger teens should also be tested if they are at high risk of acquiring an STI. For individuals at high risk of HIV infection, yearly testing is advised.

For hepatitis C, the CDC recommends screening for individuals born between 1945 and 1965. This age group has a higher incidence of hepatitis C, and the disease often progresses without noticeable symptoms. Vaccines are available for hepatitis A and B, and individuals who test negative for these viruses can consider vaccination to prevent future infections.

By following these screening recommendations, individuals can detect and address infections in a timely manner, leading to appropriate treatment and prevention measures. Regular screenings are essential for maintaining sexual health and overall well-being.

Pharmacogenetic Testing

Pharmacogenetic testing, also known as pharmacogenomics, examines how genes influence an individual's response to specific medications. Genes, inherited from both parents, carry information that determines unique traits and can impact the safety and efficacy of drugs.

Advantages:

Personalized Medicine: Pharmacogenetic testing helps identify the types of medicines and dosages that may be most suitable for an individual. This personalized approach improves treatment outcomes by selecting medications tailored to a person's genetic makeup.
Enhanced Efficacy: By understanding an individual's genetic profile, healthcare providers can choose medications that are more likely to be effective for that specific person. This can save time and resources by avoiding trial-and-error approaches to find the right treatment.
Minimized Adverse Effects: Genetic variations can influence how individuals metabolize drugs, making them more susceptible to side effects. Pharmacogenetic testing can predict whether a person is at risk of experiencing severe adverse reactions, allowing for adjustments in medication choices or dosages to prevent harm.

Disadvantages:

Limited Availability: Currently, pharmacogenetic tests are only available for a restricted number of medicines. The range of medications covered by these tests continues to expand, but it may not encompass all prescribed drugs.
Interpretation Challenges: Analyzing and interpreting genetic test results require expertise in pharmacogenetics. Ensuring accurate and meaningful interpretations of genetic variations can be complex, requiring trained healthcare professionals.
Cost and Insurance Coverage: Pharmacogenetic testing may not be covered by all insurance plans, leading to potential out-of-pocket expenses for patients. The cost of testing and subsequent medication adjustments should be considered.

Pharmacogenetic testing is ordered by healthcare providers when starting a new medication or when evaluating the effectiveness or adverse effects of a current treatment. It offers valuable insights into medication selection, dosage optimization, and the potential for serious side effects. However, it is important to note that not all medications have corresponding genetic tests available, and interpretation of results requires expertise in the field.

Hereditary Risks Assessment or Cancer Genomics

Advantages and Benefits of Genetic Testing for Hereditary Cancer Risk:

Personalized Risk Assessment: Genetic testing provides a comprehensive evaluation of your personal and family history of cancer, enabling the identification of potential hereditary cancer risks. This personalized risk assessment helps determine the appropriate management strategies and screenings for your specific situation.
Informed Decision-Making: With the knowledge gained from genetic testing, you can make informed decisions about your healthcare. Understanding your genetic predisposition to certain types of cancer empowers you to take proactive steps in managing your future cancer risks.
Tailored Screening and Prevention: Genetic test results can guide your healthcare provider in developing a personalized care plan based on your individual risk profile. For instance, if you are at a higher risk of breast cancer recurrence, additional screening methods such as breast MRIs may be recommended. If you have an inherited risk for breast cancer, preventive measures to reduce the risk of developing ovarian cancer can be explored.
Early Detection and Treatment: Genetic testing can determine whether your cancer resulted from an inherited gene mutation. This information is crucial in understanding the underlying causes and can impact treatment decisions. Additionally, if you have an increased risk of developing a second cancer, appropriate surveillance and early intervention can be initiated.
Support from Genetic Counselors: Genetic counseling is often provided before and after genetic testing. This counseling session allows you to address any concerns, ask questions, and gain a deeper understanding of the role of genes in cancer development. Genetic counselors provide guidance, emotional support, and help interpret the test results, ensuring you have the necessary information to make well-informed choices.
Sample Collection Options: Genetic testing can be performed using various DNA sources, such as blood, saliva, or mouthwash samples. This flexibility in sample collection enhances convenience and accessibility for individuals undergoing testing.

Genetic testing for hereditary cancer risk offers numerous advantages, including personalized risk assessment, informed decision-making, tailored screening and prevention strategies, early detection, and the support of genetic counselors. It provides valuable information to guide healthcare providers in developing individualized care plans, empowering patients to take proactive measures in managing their cancer risks.

Respiratory Pathogen Testing

Advantages and Benefits of Respiratory Pathogens Panel Testing:

Comprehensive Detection: A respiratory pathogens (RP) panel provides a comprehensive assessment of various viral and bacterial pathogens that can infect the respiratory tract. This enables healthcare providers to accurately diagnose the underlying cause of respiratory symptoms and determine the appropriate treatment plan.
Time and Convenience: Unlike traditional viral and bacterial tests that target one specific pathogen at a time, an RP panel requires only a single sample for testing. This streamlines the testing process, eliminating the need for multiple samples and reducing the time and effort required for diagnosis. Results from an RP panel are typically available within a few hours, allowing for prompt initiation of the most appropriate treatment.
Rapid Diagnosis: Faster results from an RP panel enable healthcare providers to diagnose respiratory infections sooner. Early diagnosis can be crucial in initiating timely and effective treatment, especially for severe illnesses like COVID-19 or respiratory syncytial virus (RSV). Rapid diagnosis helps prevent disease progression, reduces complications, and improves patient outcomes.
Targeted Treatment: Different pathogens require specific treatments. By identifying the specific virus or bacteria causing the respiratory infection, an RP panel helps healthcare providers tailor treatment plans to the individual patient. This improves the likelihood of successful treatment and minimizes the use of unnecessary or ineffective medications.
Enhanced Infection Control: Rapid identification of pathogens through an RP panel enables healthcare providers to implement appropriate infection control measures promptly. This helps prevent the spread of contagious respiratory infections within healthcare settings and the community at large.
Versatility: An RP panel can detect a wide range of viral and bacterial pathogens, including those responsible for common infections like the flu, common cold, respiratory syncytial virus (RSV), adenovirus, COVID-19, whooping cough, and bacterial pneumonia. This versatility makes RP panel testing a valuable tool in diagnosing various respiratory illnesses.

In summary, respiratory pathogens panel testing offers the advantages of comprehensive detection, time efficiency, rapid diagnosis, targeted treatment, improved infection control, and versatility in detecting a wide range of viral and bacterial pathogens. These benefits contribute to more accurate diagnoses, timely interventions, and better patient care in the management of respiratory infections.